Literature DB >> 28591122

CAR-T death strikes Kite.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28591122     DOI: 10.1038/nbt0617-492

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  First approval in sight for Novartis' CAR-T therapy after panel vote.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2017-08-08       Impact factor: 54.908

Review 2.  Emerging Cellular Therapies for Cancer.

Authors:  Sonia Guedan; Marco Ruella; Carl H June
Journal:  Annu Rev Immunol       Date:  2018-12-10       Impact factor: 28.527

Review 3.  Cancer immunotherapy: broadening the scope of targetable tumours.

Authors:  Jitske van den Bulk; Els Me Verdegaal; Noel Fcc de Miranda
Journal:  Open Biol       Date:  2018-06       Impact factor: 6.411

4.  T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell.

Authors:  Sai Liu; Jianping Sun; Zhen Li; Ling Qin; Guihai Liu; Kang Li; Hao Wu; Tao Dong; Yonghong Zhang
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 7.561

5.  Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity.

Authors:  Na Zhang; Jingbo Shao; Hong Li; Jiashi Zhu; Min Xia; Kai Chen; Hui Jiang
Journal:  J Immunother       Date:  2022-08-29       Impact factor: 4.912

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.